HealthQuest leads $26.5 million investment into BioIQ

HealthQuest led a $26.5 million investment into BioIQ, the leading platform for orchestrating health testing programs and biometric screening events across multiple vendors.  Additionally, BioIQ utilizes multi-channel communication tools for engaging and motivating participants.  HealthQuest was joined in this investment by Arboretum Ventures and select insiders. 

Read More
Randy Scott
HealthQuest participates in follow-on financing for Venus Concept

HealthQuest Capital, EW Healthcare partners and Madryn Asset Management invested an additional $7 million in Venus Concept concurrent with the completion of the acquisition of NeoGraft.  NeoGraft is an industry leader in the area of hair restoration technologies.  Venus Concept's industry first and only subscription-based business model, combined with its global reach in over 60 countries and 27 direct global offices, will create a significant opportunity to expand the overall combined businesses of both NeoGraft and Venus Concept.

Read More
Randy Scott
HealthQuest leads $20 million investment into Springbuk

HealthQuest led a $20 million investment into Springbuk, the leading employer-facing health intelligence software.  HealthQuest was joined in this investment by Echo Health Ventures and Lewis & Clark Ventures.

Springbuk was founded in 2015 by Rod Reasen and Phil Daniels, co-founders of the Healthiest Employers awards program, with the mission to empower employers to lower their healthcare costs by harnessing their health data. Today, over 1,000 employers use Springbuk’s software to glean actionable insights to improve their population’s health.

Read More
Randy Scott
Castle Biosciences Launches Next-Generation Sequencing Panel for Uveal Melanoma

Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the launch of the DecisionDx®-UMSeq panel that uses next-generation sequencing (NGS) to identify somatic mutations in genes relevant to uveal melanoma (UM). The new test will complement Castle Biosciences’ standard-of-care DecisionDx®-UM gene expression profile (GEP) test that has been shown to be independent of and superior to mutational analysis in assessing likelihood of metastasis in UM.

Read More
Randy Scott
Garheng Kong selected for Aspen Institute's Health Innovators Fellowship

HealthQuest Capital Managing Partner, Dr. Garheng Kong, was selected as one of 21 healthcare industry leaders to participate in the Aspen Insitute's Health Innovators Fellowship. He and the other fellows will participate in a two-year Fellowship designed to strengthen the leadership of innovators across the US health care ecosystem and challenge them to create new approaches to improve the health and well-being of all Americans.

 

Read More
Randy Scott
HQC portfolio company Spirox acquired by Entellus

Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering minimally invasive ENT procedures, today announced that it has entered into a definitive agreement to acquire Spirox, Inc., a privately-held ENT medical technology company that develops, manufactures and markets the LATERA™ Absorbable Nasal Implant, a minimally invasive option for ENTs and facial plastic surgeons to treat nasal airway obstruction. 

Read More
Randy Scott
Trice Medical Closes $19.3 Million Series C Financing

Trice Medical announced today that it closed a $19.3 million Series C financing and will use the proceeds to accelerate and expand the company's U.S. market penetration for mi-eye2™, R&D, sales, marketing and key international regulatory approvals. Smith & Nephew (LSE:SN, NYSE: SNN) has taken a minority stake joining a consortium of current investors including HealthQuest.

Read More
Randy Scott
HealthQuest Joins Syndicate for $42M Investment in Avedro

Avedro, Inc., an ophthalmic pharmaceutical and medical device company and world leader in corneal remodeling, today announced that it secured a combined $42 million in equity and debt financing. The equity financing was led by HealthQuest Capital, with strong support from existing investors OrbiMed Advisors and InterWest Partners. 

Read More
Randy Scott
Blue Cross/Blue Shield Issues Positive Assessment of Castle Bioscience Test

Friendswood, TX – March 29, 2017 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced that Blue Cross Blue Shield Association Evidence Street™ has issued a positive assessment of DecisionDx®-UM, the Company’s gene expression profile (GEP) test to determine prognosis (metastatic potential) in patients diagnosed with uveal melanoma (UM). Evidence Street provides objective information to healthcare and managed care professionals based on clinical and scientific evidence and evaluates whether a technology could improve net health outcomes

Read More
Randy Scott